格林巴利症候群 (GBS) 市场 - 按治疗类型、类型、性别、年龄层、最终用户 - 全球预测

在患者意识不断增强的推动下，2024 年至 2032 年全球格林巴利症候群 (GBS) 市场复合年增长率将达到 4.6%。提高患者和倡导团体对格林巴利症候群 (GBS) 症状、治疗选择和支持性护理的认识，在其管理中发挥关键作用。这种意识的提高可以更早识别症状，促进及时的医疗干预并改善患者的治疗结果。

根据美国国家神经疾病和中风研究所 (NINDS) 的报告，患者意识的提高和宣传工作使格林-巴利综合症的早期诊断和治疗激增 20%，显着改善了患者的治疗结果和管理。

宣传工作有助于增加 GBS 疗法研究和支持服务的资金，从而改善整体患者护理。透过对患者和医疗保健提供者进行教育，倡导团体帮助确保受 GBS 影响的个人得到及时和适当的治疗，从而有可能减少病情对患者生活影响的严重程度和持续时间。

整个吉兰-巴利综合症 (GBS) 市场根据治疗类型、性别、类型、最终用户、年龄组和地区进行分类。

到 2032 年，支持性治疗领域将呈现强劲的复合年增长率。此外，医疗技术和治疗方法的进步扩大了支持治疗的范围，为患者提供了更多缓解不适和促进復原的选择。此外，随着医疗保健系统强调整体患者护理，人们越来越重视在整个治疗过程中提供全面支持，从而推动了针对 GBS 患者独特需求的支持疗法的需求。

到2032年，由于更好的诊断能力，慢性发炎性脱髓鞘多发性神经病变（CIDP）细分市场将获得相当大的吉兰-巴利症候群（GBS）市场份额，从而提高CIDP病例的识别率。 CIDP 和 GBS 治疗方案的重迭（均涉及免疫调节疗法）推动了该领域对专业护理的需求。此外，透过早期准确的诊断来改善患者的治疗效果可以鼓励积极主动的治疗，从而刺激对标靶治疗的需求。此外，神经学研究的医疗保健投资不断增加，进一步促进了这些疾病有效治疗方法的开发和可用性。

由于人口老化，更容易罹患自体免疫疾病，欧洲格林巴利症候群 (GBS) 市场从 2024 年到 2032 年将出现显着的复合年增长率。此外，欧洲对医疗基础设施和研究的投资增加也改善了获得先进医疗保健和创新疗法的机会。专注于早期诊断和全面患者护理的公共卫生措施推动了需求的不断增长。欧洲神经病学协会提高认识活动和支持正在引导更多患者寻求及时有效的治疗，从而提振了市场。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • GBS 发生率增加
    • 人们对罕见疾病治疗的认识不断增强
    • 政府扶持政策及资金
    • 扩大研发投入
    • 诊断和治疗的进步
  • 产业陷阱与挑战
    • 治疗的不良反应
    • 监管和报销挑战
• 成长潜力分析
• 管道分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 一线治疗
  • 静脉注射免疫球蛋白 (IVIG)
  • 血浆交换（血浆去除术）
• 支持治疗

第 6 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 急性发炎性脱髓鞘多发性神经病变（AIDP）
• 慢性发炎性脱髓鞘多发性神经根神经病变（CIDP）
• 米勒费雪症候群 (MFS)
• 急性运动轴突神经病变（AMAN）
• 其他类型

第 7 章：市场估计与预测：按性别划分，2021 - 2032 年

• 主要趋势
• 男性
• 女性

第 8 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• 20岁以下
• 21-40岁
• 41-59岁
• 60岁以上

第 9 章：市场估计与预测：按最终用户划分，2021 - 2032 年

• 主要趋势
• 医院
• 诊所
• 復健中心
• 其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• AbbVie Inc.
• Biogen Inc.
• Cadila Healthcare Limited
• CSL Behring LLC
• F.Hoffmann-La Roche Ltd.
• GSK plc
• Grifols SA
• LGM Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Octapharma AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited

Global Guillain-Barre Syndrome (GBS) Market will record a 4.6% CAGR from 2024 to 2032, driven by growing patient awareness. Greater awareness among patients and advocacy groups about Guillain-Barre Syndrome (GBS) symptoms, treatment options, and supportive care plays a pivotal role in its management. This heightened awareness leads to earlier recognition of symptoms, facilitating prompt medical intervention and improving patient outcomes.

As per the National Institute of Neurological Disorders and Stroke (NINDS) report, better patient awareness and advocacy efforts have led to a 20% upsurge in early diagnosis and treatment of Guillain-Barre Syndrome, significantly improving patient outcomes and management.

Advocacy efforts contribute to increased funding for research into GBS therapies and support services, enhancing overall patient care. By educating both patients and healthcare providers, advocacy groups help ensure that individuals affected by GBS receive timely and appropriate treatment, thus potentially reducing the severity and duration of the condition's impact on patients' lives.

The overall Guillain-Barre syndrome (GBS) market is classified based on treatment type, gender, type, end-user, age group, and region.

The supportive treatments segment will exhibit a robust CAGR through 2032. As awareness of GBS increases, so does the recognition of the need for comprehensive supportive care to manage its symptoms effectively. Additionally, advancements in medical technology and therapeutic approaches have expanded the range of supportive treatments available, offering patients more options for alleviating discomfort and enhancing recovery. Moreover, with healthcare systems emphasizing holistic patient care, there is a growing emphasis on providing comprehensive support throughout the treatment journey, driving the demand for supportive therapies tailored to the unique needs of GBS patients.

The chronic inflammatory demyelinating polyneuropathy (CIDP) segment will garner a considerable Guillain-Barre syndrome (GBS) market share by 2032, owing to better diagnostic capabilities, leading to higher identification rates of CIDP cases. The overlap in treatment protocols for CIDP and GBS, both involving immune-modulating therapies, has driven the need for specialized care in this segment. Additionally, enhanced patient outcomes with early and accurate diagnosis encourage proactive management, spurring the demand for targeted therapies. Moreover, rising healthcare investments in neurological research further bolster the development and availability of effective treatments for these conditions.

Europe Guillain-Barre syndrome (GBS) market will register a noteworthy CAGR from 2024 to 2032, because of the aging population, which is more susceptible to autoimmune disorders. Additionally, increased investments in healthcare infrastructure and research in Europe have improved access to advanced medical care and innovative therapies. Public health initiatives focused on early diagnosis and comprehensive patient care contribute to the rising demand. Heightened awareness campaigns and support from European neurological associations are guiding more patients to seek timely and effective treatments, boosting the market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of GBS
    • 3.2.1.2 Growing awareness for rare disease treatment
    • 3.2.1.3 Government supporting policies and funding
    • 3.2.1.4 Expanding R&D investment
    • 3.2.1.5 Advancements in diagnostics and treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects of treatments
    • 3.2.2.2 Regulatory and reimbursement challenges
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Competitive analysis of major market players
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 First-line treatment
  • 5.2.1 Intravenous immunoglobulin (IVIG)
  • 5.2.2 Plasma exchange (Plasmapheresis)
• 5.3 Supportive treatment

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Acute inflammatory demyelinating polyneuropathy (AIDP)
• 6.3 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• 6.4 Miller fisher syndrome (MFS)
• 6.5 Acute motor axonal neuropathy (AMAN)
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Male
• 7.3 Female

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Below 20 years
• 8.3 21-40 years
• 8.4 41-59 years
• 8.5 60 and above

Chapter 9 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Clinics
• 9.4 Rehabilitation centers
• 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Biogen Inc.
• 11.3 Cadila Healthcare Limited
• 11.4 CSL Behring LLC
• 11.5 F.Hoffmann-La Roche Ltd.
• 11.6 GSK plc
• 11.7 Grifols SA
• 11.8 LGM Pharmaceuticals, Inc.
• 11.9 Merck & Co., Inc.
• 11.10 Octapharma AG
• 11.11 Pfizer Inc.
• 11.12 Takeda Pharmaceutical Company Limited